Rowena Yip1, Kunwei Li1,2, Li Liu1,3, Dongming Xu1, Kathleen Tam1, David F Yankelevitz1, Emanuela Taioli4, Betsy Becker5, Claudia I Henschke6. 1. Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. 2. Department of Radiology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China. 3. Department of Diagnostic Radiology, Cancer Hospital, Chinese Academy of Medical Science, Peking Union Medical College, Beijing, China. 4. Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 5. Department of Educational Psychology and Learning Systems, College of Education, Florida State University, Tallahassee, FL, USA. 6. Department of Radiology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. Claudia.Henschke@mountsinai.org.
Abstract
PURPOSE: Summarise survival of patients with resected lung cancers manifesting as part-solid nodules (PSNs). METHODS: PubMed/MEDLINE and EMBASE databases were searched for all studies/clinical trials on CT-detected lung cancer in English before 21 December 2015 to identify surgically resected lung cancers manifesting as PSNs. Outcome measures were lung cancer-specific survival (LCS), overall survival (OS), or disease-free survival (DFS). All PSNs were classified by the percentage of solid component to the entire nodule diameter into category PSNs <80% or category PSNs ≥80%. RESULTS: Twenty studies reported on PSNs <80%: 7 reported DFS and 2 OS of 100%, 6 DFS 96.3-98.7%, and 11 OS 94.7-98.9% (median DFS 100% and OS 97.5%). Twenty-seven studies reported on PSNs ≥80%: 1 DFS and 2 OS of 100%, 19 DFS 48.0%-98.0% (median 82.6%), and 16 reported OS 43.0%-98.0% (median DFS 82.6%, OS 85.5%). Both DFS and OS were always higher for PSNs <80%. CONCLUSION: A clear definition of the upper limit of solid component of a PSN is needed to avoid misclassification because cell-types and outcomes are different for PSN and solid nodules. The workup should be based on the size of the solid component. KEY POINTS: • Lung cancers manifesting as PSNs are slow growing with high cure rates. • Upper limits of the solid component are important for correct interpretation. • Consensus definition is important for the management of PSNs. • Median disease-free-survival (DFS) increased with decreasing size of the nodule.
PURPOSE: Summarise survival of patients with resected lung cancers manifesting as part-solid nodules (PSNs). METHODS: PubMed/MEDLINE and EMBASE databases were searched for all studies/clinical trials on CT-detected lung cancer in English before 21 December 2015 to identify surgically resected lung cancers manifesting as PSNs. Outcome measures were lung cancer-specific survival (LCS), overall survival (OS), or disease-free survival (DFS). All PSNs were classified by the percentage of solid component to the entire nodule diameter into category PSNs <80% or category PSNs ≥80%. RESULTS: Twenty studies reported on PSNs <80%: 7 reported DFS and 2 OS of 100%, 6 DFS 96.3-98.7%, and 11 OS 94.7-98.9% (median DFS 100% and OS 97.5%). Twenty-seven studies reported on PSNs ≥80%: 1 DFS and 2 OS of 100%, 19 DFS 48.0%-98.0% (median 82.6%), and 16 reported OS 43.0%-98.0% (median DFS 82.6%, OS 85.5%). Both DFS and OS were always higher for PSNs <80%. CONCLUSION: A clear definition of the upper limit of solid component of a PSN is needed to avoid misclassification because cell-types and outcomes are different for PSN and solid nodules. The workup should be based on the size of the solid component. KEY POINTS: • Lung cancers manifesting as PSNs are slow growing with high cure rates. • Upper limits of the solid component are important for correct interpretation. • Consensus definition is important for the management of PSNs. • Median disease-free-survival (DFS) increased with decreasing size of the nodule.
Authors: E A Kim; T Johkoh; K S Lee; J Han; K Fujimoto; J Sadohara; P S Yang; T Kozuka; O Honda; S Kim Journal: AJR Am J Roentgenol Date: 2001-12 Impact factor: 3.959
Authors: Jong Ho Cho; Yong Soo Choi; Jhingook Kim; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim Journal: Ann Thorac Surg Date: 2014-11-15 Impact factor: 4.330
Authors: David S Gierada; Paul Pinsky; Hrudaya Nath; Caroline Chiles; Fenghai Duan; Denise R Aberle Journal: J Natl Cancer Inst Date: 2014-10-18 Impact factor: 13.506
Authors: Benedikt H Heidinger; Mario Silva; Constance de Margerie-Mellon; Paul A VanderLaan; Alexander A Bankier Journal: Transl Lung Cancer Res Date: 2019-12
Authors: Qingpeng Zeng; Bingzhi Wang; Jiagen Li; Jun Zhao; Yousheng Mao; Yushun Gao; Qi Xue; Shugeng Gao; Nan Sun; Jie He Journal: Cancer Manag Res Date: 2020-09-08 Impact factor: 3.989
Authors: Claudia I Henschke; Rowena Yip; Dorith Shaham; Javier J Zulueta; Samuel M Aguayo; Anthony P Reeves; Artit Jirapatnakul; Ricardo Avila; Drew Moghanaki; David F Yankelevitz Journal: J Thorac Imaging Date: 2021-01 Impact factor: 5.528